Skip to content
WorldBrand.AI

Kartos Therapeutics, Inc.

Recent events

Recent events tied to this brand in public sources.

Back to profile1 entries

  1. 2026

    Ipsen completes acquisition of Kartos Therapeutics

    Ipsen announced on 21 August 2026 that it completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company, adding the late-stage MDM2 inhibitor navtemadlin, which is in Phase III clinical development for myelofibrosis.

    Source